Magenta Therapeutics Stock Fundamentals
Magenta Therapeutics fundamentals help investors to digest information that contributes to Magenta Therapeutics' financial success or failures. It also enables traders to predict the movement of Magenta Stock. The fundamental analysis module provides a way to measure Magenta Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Magenta Therapeutics stock.
Magenta |
Magenta Therapeutics Company Return On Asset Analysis
Magenta Therapeutics' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Magenta Therapeutics Return On Asset | -0.29 |
Most of Magenta Therapeutics' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Magenta Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
CompetitionBased on the latest financial disclosure, Magenta Therapeutics has a Return On Asset of -0.2885. This is 96.7% lower than that of the Biotechnology sector and 98.78% lower than that of the Health Care industry. The return on asset for all United States stocks is 106.07% higher than that of the company.
Magenta Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Magenta Therapeutics's current stock value. Our valuation model uses many indicators to compare Magenta Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Magenta Therapeutics competition to find correlations between indicators driving Magenta Therapeutics's intrinsic value. More Info.Magenta Therapeutics is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Magenta Therapeutics' earnings, one of the primary drivers of an investment's value.Magenta Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Magenta Therapeutics' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Magenta Therapeutics could also be used in its relative valuation, which is a method of valuing Magenta Therapeutics by comparing valuation metrics of similar companies.Magenta Therapeutics is currently under evaluation in return on asset category among its peers.
Magenta Fundamentals
| Return On Equity | -0.65 | |||
| Return On Asset | -0.29 | |||
| Current Valuation | (32.66 M) | |||
| Shares Outstanding | 60.66 M | |||
| Shares Owned By Insiders | 2.23 % | |||
| Shares Owned By Institutions | 62.63 % | |||
| Number Of Shares Shorted | 383.03 K | |||
| Price To Earning | (1.63) X | |||
| Price To Book | 0.54 X | |||
| EBITDA | (78.98 M) | |||
| Net Income | (76.46 M) | |||
| Cash And Equivalents | 128.28 M | |||
| Cash Per Share | 2.13 X | |||
| Total Debt | 29.96 M | |||
| Debt To Equity | 0.25 % | |||
| Current Ratio | 10.22 X | |||
| Book Value Per Share | 1.24 X | |||
| Cash Flow From Operations | (67.09 M) | |||
| Short Ratio | 1.38 X | |||
| Earnings Per Share | (1.11) X | |||
| Target Price | 1.0 | |||
| Number Of Employees | 67 | |||
| Beta | 2.12 | |||
| Market Capitalization | 45.14 M | |||
| Total Asset | 146.65 M | |||
| Retained Earnings | (402.03 M) | |||
| Working Capital | 101.05 M | |||
| Current Asset | 33.34 M | |||
| Current Liabilities | 3.39 M | |||
| Z Score | -3.88 | |||
| Net Asset | 146.65 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Other Consideration for investing in Magenta Stock
If you are still planning to invest in Magenta Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Magenta Therapeutics' history and understand the potential risks before investing.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |